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A human malignant m elanom a maintained in athymi c nude 
mice has been successfull y implanted and grown in cy-
c1osporine (Cys)-il11l11unosuppressed Lewis rats . Sus-
pended melanoma cells (106) or so lid tumor sections m ea-
sming 2-4 mm in diameter were implanted s. c. in ra ts 
receiving parenteral Cys doses of 15-50 mg/kg each day 
for 1 week, and 3 times per week thereafter. Eighty-five 
percent of solid tumor sections jITlplanted in animals re-
ceiving 25 m g/kg resulted in tumo r grow th, whereas no 
tumors g rew from cell suspension injection sites. Th e av-
I n recent years there has been extens ive use of hum an tumor xenografts 1Il anim al m odels for th e study of the biology and therapy of human cancer [1-6]. These inves tigations have been variabl y successful in their attemp ts to es tablish hum an tumor xenog raft systems that maintain the parent 
tumor's bio logic beha vior and sensit ivity to therap y. All of th ese 
models have utilized as hosts either genetica ll y immunodefi cient 
anim als such as the nude mouse and rat 1.1-3], o r pos tnatall y 
immunosuppressed anim als such as irradiated, th y m ectomized , 
and/o r chemotherapy-treated an im als [4-6]. The most w idely 
used of these m odels has been the athymic nude mo use. Steel and 
Peckham [7] have noted th at the cho ice between nude mi ce and 
imm unosuppressed mice is a difficult o ne, due to fa cto rs such as 
the cost and aseptic m aintenan ce requirements of nud e mice, and 
the tendency of rej ection m echanism s to return in animals im-
mu nosuppressed by conventional techniques, such as thymec-
tomy, irrad iation, and limited chemotherapy. 
Cyclospo rine (Cys) is a potent immunosuppressa nt used clin-
ica ll y for allogeneic o rgan transplantati on . Experimentall y, Cys 
has allowed successful xenograftin g of both norm al and malignant 
human tissue. Recentl y, H oogen hout et al [8] we re success ful in 
Manuscript received March 21 , 1986; accepted fo r publica tion August 
13, 1986. 
Supported in part by U.S. Public Health Serv ice grant AM 271'JO from 
the National Institutes of Health and by the Southern Ca liforni:l Der-
matology Foundation. 
*Presented in part at the Western Region of The Society for In vesti-
gative Dermatology, In c. , February '1985, Carm el, California , and at the 
Joint International Meeting of The Society fo r In vestiga ti ve Dern1Jtology, 
In c. , and The Japanese Society for Investigative Dermatology, Ma y 1-5, 
1985, Washington , D.C. 
Reprint requests to: Matthew M. Good man. M.D., Department of 
Derm atology, University of California , Irvinc, California Collegc of 
Medicine, Irvine, California 92717. 
Abbreviation: 
Cys: cyclosporinc 
erage maximum tumor growth rate was 2 cm 3 /da y, with 
a doubling tim e of 8 da ys. Tumors retained pretransplant 
gross and microscopic m orphology, karyotype , and la-
belin g index. Possible advantages of this model over the 
athymi c nud e m ouse includ e g reater longevity, larger an-
im al and tum or size, and less stringent aseptic environ-
mental requirements. This model may prove useful for 
further study of the pathophysiology of m elanoma and for 
tes tin g of new anti m elano ma therapies. J Jllllest Derll1ato! 
88:141-144, 1987 
xenog raftin g a hum an aden ocarcin o ma, lIIaintained as a xenograft 
in nude mi ce, to Wi star rats immunos uppressed w ith a co mbi-
nat ion o f to tal lympho id irradiation , cyclo phosphamide, and Cys 
in alternate-day doses of20- 30 ITI g/ kg . H owever, they were un-
able to xenograft th e adenoca rcinoma w hen Cys was lIsed alone 
o r in co mbinatio n with cyclo phosphamide. 
This stud y presents the success ful de velopment and characte r-
iza tion of a model o f hum an m elano ma in vivo usin g Lew is rats 
imlTlunosuppressed w ith Cys alone . 
MATERIALS AND METHODS 
Experimental Animals Male Lewis rats weighin g 250-350 g 
were purch ased and kept under standard housing conditio ns o f 
the Animal Reso urces Fa cility o f the University of Ca lifo rnia , 
Irvine. Animal s were all owed food pellcts and water ad libitum . 
T ylos in (E lanco Produ cts Co mpan y, Indi anapoli s, Indi ana), an 
ora l broad-spectruITI antibiotic, wa s added to drinkin g water at 
a dose of app roxim ately 3 m g / ml foll o win g tllm or implantation. 
Tumor Line and Implantation The hum an melanoma lin e 
SR was obta ined by surg ica l excisio n from a patient w ith m eta-
stati c cutaneous m ali gnant mel anoma in 1977, and subsequ entl y 
maintain ed by serial xenog ra ft in g in athy mi c nude mi ce. These 
experiments were done at approximatel y the 85th passage. 
Tumor-bearing nude mi ce were used as donors and sacrifi ced 
by cervica l dislocation . Tumo rs were ex cised under aseptic con-
ditio ns. Tum o r ceJl suspensio ns were m ade by fo rceps dissection 
in no rm al saline fo llowed by filtrati on throu g h sterile ga uze. Vi-
ability of cells in suspension was confirm ed by the trypa n blue 
ex clusion stain, and averaged approximately 70%. Indi vidual tu -
m or sections were cm into frag ments of 2- 4 mm di am eter. 
Tumor was xenografted to experimental rats by one of two 
techniqu es. Gro up 1 received s. c. in oculati on o f'l-2 X 106 ce lls 
suspended in 0 .2 1111 no rm al saline in each of 2- 4 dorsa l sites . 
G roup 2 received s.c. implantation o f approx imately 2-4 111m 
diameter solid tum o r section s in each of 2-4 dorsal sites under 
general anes thes ia, using intramuscula r ketamine (30 I1l g/ kg) and 
xylazine (5 m g/ kg) . 
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Table I. T umo r Suspension Im plantat io n (10(' cells per site) 
No. 
No. (No. Successful (Percent 
Si tcs Anima ls) Treatment Grafts Take) 
48 (15) CS A 15 mg/ kg 0 (0) 
24 (6) Vehicle . 0 (U) 
12 (4) CSA 25-50 m g/kg 0 (0) 
Treahnent Schedule C yclosporine. a genero us gift of Sa nd oz. 
Ltd. (Basel. Switzerlan d). was obtained as an aq ueous-insolu ble 
crys talline powder and dissolved in 20% Tween 80 in 70% ethanol 
fo r s.c . admin istration. Experim ental anim als received Cys in 
doses ran g in g from '/5- 50 Illg/kg. Contro l animals received equal 
vo lumes of vehicl e alone . Doses were admini stered S.c. dai ly for 
7 da ys and then 3 tim es per week thereafter. 
Turnor Growth and Characterization T he number of suc-
cess ful rat xenografts was expressed as a percentage of those at-
temp ted. Tumors we re photog raphed every 1-2 weeks. Routin e 
H & E-sta ined paraffin-embedded slides were prepared at va rio us 
in te rvals and compa red wi th nude mouse donor' tUlll o r sections. 
T hree-dimensio nal ca liper m eas urements were taken at regu lar 
inte rva ls. The volume was approxi m ated by the fo rmula V = 7T 
X (mean diameter?16. No correction fo r skin thickness was made. 
Labe ling indi ces of xenografts wcre dcterl1lined by in cubatin g 
tum or frag m cnts in 5 ml Gibco Medi a 199 conrainin g lO }.LC i/ 1ll1 
I-' HJ-th Yll1idin e (sp act 41 C i/ ll1lll o l) for 1 h in a shakin g water 
bath at 3rc. Smears of thcse prepa rat ions wcre preparcd fo r 
auto radi og raph y and scored as (no. labeled cell s/ no. tota l cell s) 
X 100'Yo. Karyoty pill g to dete rmin e the number o f chro m oso mes 
per cell was done acco rding to a m od ifi cation of the techniqu e of 
Nclso n-Rees et al [9]. 
G ross and mi crosco pic ap pea rances of tuill o rs in dono r mi ce 
and recip ient rats were compared. N ecrops ies were performed 
Oll representati ve anin"la\s. T um o r vo lume, grow th rates, and 
label ing indices o f tumors in donor and recipient hos ts we re CO I11-
pared . Anima ls were regularl y we ighed and serum urea nitrogen 
was measured to mo nito r Cys tox icity . 
RESU LTS 
Cell Suspension Group Fo rty-eight tUlll or cell inoculation sites 
in 15 an imals receiving 15 mg/kg Cys resulted in no tum or growth 
(0%). Twenty-four sites in 6 contro l anim als receiving vehicle 
alo nc also f.1 ilcd to g row tumor (0%). Lik ewisc. 12 sites in 4 
an imals receiving hig her doses rangin g from 25-50 Il1 g/kg Cys 
fa iled to g row tum ors (0%) (Ta ble I) . 
Solid Tumor Section Group Twenty sites in 6 anim als re-
ceivin g 25 mg/ kg Cys res ulted in g rowth at 17 sites (85%). No 
tumors g rew in 12 sites in 4 vehi cle control anim als (0%) (Table 
II ) . 
Tun"lor Volun"le Growth Successful xenog rafts g tew at var-
ious rates (Fi g 1). Max imum tumor vo lume g rowth rates in nude 
mi ce and Cys-trcated rats we n: similar at approx imatel y 2 Clll" 
per da y. T he m ax imum tumor doublin g time in both was 8 days. 
A 14-day delay in the onset of max imal g rowth rate betwccn 
nude mi ce and Cys-trca red rats was noted (sec Fig I). T hi s was 
Table II. Solid TUl110r Im planta ti on (2-4 111m dia m eter) 
No. No. 
Grafts (No. Successful (Percent 
Attempted Anim als) Trca(ment Grafts Take) 
20 (6) CSA 25 m g/kg 17 (85) 
12 (4) Vehicle 0 (0) 
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Figure 1. CO l1lparat ivc grow th clIrves of "lill Ian lllel all Olll a xC ll og raft , 
Solid !ill(, = Cys-trcated rat . so li d tlllll or illlplams; &""/:1'11 /ill (, = Illld~ 
IllOl/se. suspells io ll illOClIla . 
Ill os t li ke ly due to the g reate r tum or inoculum size in the rats 
( 107_10" cells) co mpared w ith the mi ce ('10" cell s). 
Karyology A verage chrOlllosome co unts of tumor cell s in Cy _ 
treated ra ts showed a stable dip lo id number of 46 chro m osome . 
Morphology Grossly. in both nude mice and Cys-treated rats, 
tumors appeared h yperpig m cntcd and Illulti lobulated (Fi g 2). If 
all owed to g row to m assive sizes . the central portions becamt' 
necrotic and fluid-fill ed. O ld er tUlllors often eroded the sur£1Ct' 
ep itheli um and bled spontaneo usly. N ecropsics of both mi ce and 
rats consistentl y failed to show an y ev idcn ce of lll etasta tI c tu mor 
to lungs. brain. o r other o rgans.. . . 
Microsco pica ll y. tum o r tiss ue in both mi ce and rats was sllndar. 
TUlll o r ce lls werc characterized by large. baso philic nuclei with 
prominent nucl eoli . and an in creascd nu clear/cy toplas mic ratio. 
Melanin granules were present wi thin the cy to plasm. Some of 
the mo re central sections showed mark ed necros is (Fig 3). 
Labeling Index Average tumor labeling indi ces fro ill the orig-
in al patient, th e nude m ouse. and the Cys-treatcd rat hosts were 
quite similar. at 11 .6%, 10.9%. and 11. 0%. respectively (Fig 4). 
Toxicity There was an average weight loss of 10-'15% in ex-
perim ental animals over the coursc of th e ex perim ent. Som c rat 
m aintained o r ga ined we ig ht. Se rum urea nitrogen was found to 
be approx imately 30% elevated at 35 mg/d\ (no rm al up to 27 
m g/dl) at Cys doses of 25 lllg/ kg g iven 3 times weekl y. Thret' 
of 25 Cys-treaced rats developed clini ca l and his tologic eV idence 
of lun g infecti ons consistent w ith a coin cident labo rato ry occur-
rence of Mycop lasl/la pneulll o nia. In general. the Cys mallltenance 
dose of 25 m g/ kg inj ected 3 times wcek ly was tolerated for up 
to '12 weeks. No anim al dea th s wcre direct ly attributab le to a 
toxic effect ofCys. All anim als were terminated upon co mpleti on 
of the ex periment or sooner, as tum o r load beca me excess ive. 
D ISC U SSIO N 
We have llsed Cys as the sole immunosuppressant for successful 
graftin g and maintenance of a specifi c cell line of human m ela-
no m a in genetica ll y immunocompetent rats. We ha ve show n that 
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Figure 2. Gross appea ran ce of hUlllan llIelanollla xenografts. Nude 1l1ouse 
(A) and Cys- treated rat (13). Note hypcrpiglllenrari on Jnd 1l1u ltilobubtion. 
the wmo r's gross and mi crosco pi c m o rph o logy, g rowth rate, and 
la bel in g index rem ained CO nstant fro III nude m o use to Cys- tn:a ted 
rat hosts. 
The illlmunos uppl"CsSJ nt Cys is a uni q ue cycli c po ly peptide 
derived fro m th e fung us Tolypvcladi/ll/l il! f/a llllll Car ll s. Alth o ug h 
its mechanis m of act ion is no t co mpletely und erstood , ev id ence 
sugges ts that it acts pn:ferL'lltiall y o n T lymph ocytes, especia ll y 
du rin g mitogeni c s tim ul at io n of immunocompetent ce lls b y an 
ant igeni c s timu lu s 11 0, 111. Cyclos po rin e appan:ntl y suppresses 
the release of the m acro phage fa c to r illterleukin I , w hi ch is nec-
essary for the ac ti va ti o n o fT lymph ocy tes, and inhibits produc-
Figure 3. Microscopic appearance of hUlllan 1l1ebnOlll a xenografts. Nude 
mouse (A) and Cys-trea ted rat (13). TU lll or ce lls appea r ana plas tic \Vi th 
large basoph ilic nuclei , prominent nllck o li , and i/lcreased /lucie-ar! 
cytoplasmic ratio. 
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Figure 4. Comparative labelin g indices of nl L·tastaric h'llllall III e1ano III a 
in situ in donor patiellt and in xcnograftecl :llliIll als. 
tio n and release o f th e T-/ymph ocy te IYJllplr okine in terleukin 2, 
w hich stimu lates pro liferation o f activated T lymphocy tes 11 21. 
T helper ce ll s arc relativel y 11l 0 re affected than T su pp resso r ce lls 
11 3-151. Inte restin g ly, these act io ns take place in the pe ri pheral 
blood, thu s avo idin g di rect bon e m arrow toxicity 11 61. and are 
reve rsible upo n w ithdrawa l of the drug 11 71. In a limited fo ll ow-
up experiment, we co nfirm ed the revers ibili ty of th e im Jllun o-
sup press io n of Cys b y takin g 2 Cys- tre:!ted rats, each bea rin g 4 
tum o rs, and di scontinuin g Cys in o ne and decreasi ng the dose 
fro m 25 m g/ kg to 15 m g/kg in the o ther. After -t weeks, a ll 
tUlll o rs in bo th anim als had cO lllpletely reg ressed and we re un-
detectable . 
T he in ab ility of 10(' ce ll s in suspensio n to p rod uce tum o rs was 
lik ely d ue to in adequate ce ll numbers to survive the rats ' n:-
l113i lling II o nsuppressed rejection nll:chanis m s. The so li d tumor 
sectio ns, m easurillg up to 4 mm ill d iam eter, pro babl y contained 
10- 100 times as mall Y cel ls as ce ll suspension in ocula. An other 
fac lor m ay have been tlut the tum o r ce ll s located in the center 
of the so lid secti o ns were no t accessible to ce llular rejectio ll mech-
ani sm s beca use of their reiJtive ph ys ica l seq ues trat io n . Pu b lished 
tak e rates for fres h hum an m etastatic me lano m a xenografts ill 
nu de mi ce are 77-80% 11 8. I Sl i. It is no t kn ow n w hether th e Cys-
treated rat d iffers frol11 nud e mice in thi s respect. The m elan o m a 
used ill the current s tud y was taken frol11 all a lrea d y esta blish ed 
xenog raft li nc ca rri ed in nud e mi ce and therefore prese lec ted fo r 
its ab ility to g row as a xeno g raft. We ha ve m ade an attcmpt in 
this rat m o del to implant freshl y exci sed 11ll:iJn o m a from a patient 
with cutaneous m eta stases. All -t of the implanted sect io ns fa iled 
to g row. It wi ll be necessa ry to repeat fresh tum o r xenografts 
fro m multi ple patients to esta blish thi s 111 0del's take ra te fo r tu-
111 0 rs tak en directl y fro m patients. 
T here arc several advantages of this new m odel over the athy mic 
nud e m o use. The Lewis rat 's IIatura l li fespa n is lo nger th an the 
nud e. In addition , beca use of th e rat " brger size, it is able to 
m aintain brger tum o r g row th , an d thus tum o r load, for at least 
twi ce as lo ng as th e nude m o use. In o ur ex periments, tum o r-
bea rin g mi ce lived an ave rage of 5-7 weeks from the tim e of 
tum o r in oculatio n befo re succumbing to the tum or, co mpared to 
10-12 weeks in the ra ts. H owever, the tum o r in ocu lu m size was 
mu ch g rea ter in th e rats. Ifinitia l inocu lul1l s izes had been eq ual, 
the differen ce in lo ngev it y mi g ht have been m o re pro noun ced. 
T his m o del also prov ides g reater sur face area fo r multiple tum o r 
implants o n th e sa m e ani m al. In add itio n , phleboto m y, imag in g 
studies, and drug adm ini strati o n would be teclllli ca ll y easier in 
this larger anim al. It m ay be thH the s trin gent asepti c en viro n-
m ental cond itio ns req uired fo r nu de mi ce arc no t necessa ry for 
Cys-trea ted rats, if th eir prexL:nog raft ill1 l1lun oco mpeten ce co n-
tinues to be protective fo r infecti o ns. H owever, s ig nifi ca nt lun g 
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infec ti o n s d evelo ped in 3 of25 rats, a nd h Oll s ing rats in an asepti c 
enviro nl11 ent Ill ay rcd u'ce th e in c ide nce of infec ti o us co mpli ca ti o ns 
in this m odel. 
The limita ti o ns o f this Ill odel mu s t be co ns ide re d . Side effects 
of Cys in clu de re na l tox icity , weig ht loss, h epatotox ic ity , ly m-
ph o pe ni a, a nd a n in creased ri sk for o pportuni s ti c infec ti o ns. In 
additio n, po te ntial drug interac ti o ns between Cys and J n y di-
ag n ost ic o r th e rape uti c age nts eva lua ted w ith thi s m odel Illu s t b e 
co ns ide red. We a rc a lso aware tha t this llI eth o d of tU lll o r xe11 0 -
g raftin g m ay n o t achi eve widesp read appli ca ti o n b eca use of th e 
in con veni e nce a nd expense of repeated admjnis tr:nion of Cys co 
m aintai n tulll o r g rowth. 
The po te ntia l uses of this Ill odel arc essentiall y the sa m e as 
those of t he ath Yl11i c nu de m Ollse , includin g furth e r in vivo s tud y 
of the pathoph ys io logy of human tUlll o rs alld tes till g of new 
antitulIl o r t he ra pi es. 
We ti re gl'(I /':fi" to jl'llllljCl' jmkill' nlld A lli.'I!Ii JIIlce "I'mick .fi'I' III<'i,. ('.\'ed /t'll/ 
Iccllll;C(l IOiS iSI(IIICl'. W (' nlw " ' ;sl, It> III (lIlk LOllra /J/"om fo l' 1/1'1' II el" ill 1'''('p(l'';I1,~ 
Ihis III IIIIIIScripl . 
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